|Summary sheet: LockPicker/Drafts/1cP-LSD|
|Substitutive name||1-Cyclopropionyl-d-lysergic acid diethylamide|
|Routes of Administration|
1-Cyclopropionyl-d-lysergic acid diethylamide (known as 1cP-LSD) is a novel semisynthetic psychedelic substance of the lysergamide class. It induces its psychedelic effects by acting on serotonin receptors in the brain. 1cP-LSD is closely related to 1P-LSD and LSD. It is reported to produce similar to identical effects.
Little is known about the pharmacology. Incubation of 1CP‐LSD with human serum led to the formation of LSD, indicating that it may act as a prodrug for LSD. Characteristic effects include geometric visual hallucinations, time distortion, enhanced introspection, and ego loss.
1cP-LSD appeared on the online research chemical market as a new legal alternative to LSD when 1P-LSD was prohibited in Germany.
It is highly advised to use harm reduction practices if using this substance.
History and culture
This History and culture section is a stub.
As a result, it may contain incomplete or wrong information. You can help by expanding it.
1cP-LSD first appeared on the online research chemical market in July 2019.
1cP-LSD is a semisynthetic compound of the lysergamide family. It is similar to LSD and is named for the cyclopropionyl group bound to the nitrogen of the polycyclic indole group of LSD. The cyclopropionyl group consists of a carbonyl ring with the chemical formula C3H6 bound to an amino group. The structure of 1cP-LSD contains a polycyclic group featuring a bicyclic hexahydro indole bound to a bicyclic quinoline group. At carbon 8 of the quinoline, an N,N-diethyl carboxamide is bound.
Based on its structural similarity to LSD, 1cP-LSD likely acts as a partial agonist at the 5-HT2A receptor. The psychedelic effects are thought to primarily come from its efficacy at the 5-HT2A receptors distributed throughout the brain. 1cP-LSD also likely displays binding activity at a wide range of monoamine receptors, such as those for dopamine and norepinephrine. However, there is currently no data to support these claims.
|This subjective effects section is a stub.|
As such, it is still in progress and may contain incomplete or wrong information.
You can help by expanding or correcting it.
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), a research literature based on collected anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be regarded with a healthy degree of skepticism. It is worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce a full spectrum of effects. Likewise, adverse effects become much more likely with higher doses and may include addiction, serious injury, or death ☠.
- Stimulation - 1cP-LSD is usually regarded as very energetic and stimulating without being forced. For example, when taken in any environment it will usually encourage physical activities such as running, walking, climbing or dancing. In comparison, other more commonly used psychedelics such as psilocybin which are generally sedating and relaxed.
- Spontaneous bodily sensations - The "body high" of 1cP-LSD can be characterized as proportionally very intense in comparison to its accompanying visual and cognitive effects. It behaves as a euphoric, fast-moving, sharp and location-specific tingling sensation. For some, it is manifested spontaneously at different, unpredictable points throughout the trip, but for most, it maintains a steady presence that rises with the onset and hits its limit once the peak has been reached. At moderate to high doses of 1cP-LSD, this sensation often approaches its highest level and can become so overwhelming that people may find themselves debilitated with pleasurable sensations.
- Tactile enhancement - Feelings of enhanced tactile sensations are consistently present at moderate levels throughout most 1cP-LSD experiences. If level 8A geometry is reached, an intense sensation of suddenly becoming aware of and being able to feel every single nerve ending across a person's entire body all at once is consistently present.
- Stamina enhancement - This is generally mild in comparison to the stamina enhancement produced by traditional stimulants.
- Appetite suppression
- Bodily control enhancement
- Difficulty urinating
- Excessive yawning - This effect is significantly less pronounced than it is with psilocybin and its related compounds, the four-position substituted tryptamines.
- Nausea - Mild nausea is occasionally reported when consumed in moderate to high dosages and either passes instantly soon after the user has vomited or gradually fades by itself as the peak sets in.
- Increased blood pressure
- Increased heart rate
- Increased perspiration
- Muscle contractions
- Muscle spasms
- Pupil dilation
- Increased salivation
- Vasoconstriction - Vasoconstriction may lead to users feeling cold, especially in the extremities.
- Seizure - The likelihood is largely extrapolated from the seizures that have been reported from the use of LSD. It is thought to mainly be a risk in those who are genetically predisposed to them, particularly while accompanied by physically taxing conditions such as states of dehydration, fatigue, undernourishment or overheating.
- Drifting (melting, breathing, morphing and flowing) - In comparison to other psychedelics, this effect can be described as highly detailed yet cartoon-like in its appearance. The distortions are slow and smooth in motion and fleeting in their appearance.
- Colour shifting
- Colour tinting
- After images
- Depth perception distortions
- Perspective distortions
- Symmetrical texture repetition
- Scenery slicing
The visual geometry of 1cP-LSD can be described as more similar in appearance to that of 2C-B or 2C-I than psilocin, LSA or DMT. It can be comprehensively described through its variations as primarily intricate in complexity, algorithmic in form, unstructured in organization, brightly lit, colourful in scheme, synthetic in feel, multicoloured in scheme, flat in shading, sharp in edges, large in size, fast in speed, smooth in motion, angular in its corners, non-immersive in-depth and consistent in intensity.
1cP-LSD is capable of producing a full range of hallucinatory states in a fashion that is significantly less consistent and reproducible than that of many other commonly used psychedelics, specifically tryptamines like DMT or psilocybin mushrooms. These effects include:
- Machinescapes - This component is a rare effect that typically only occurs at very strong to heavy doses, and not as consistently as with notably visual psychedelics like DMT, ETH-LAD, and 2C-P, and atypical psychedelics like salvia.
- Internal hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - Although 1cP-LSD is technically capable of producing hallucinatory states in a fashion that is on par with psilocin or DMT in its vividness and intensity, these effects are incredibly rare and inconsistent in comparison. While traditional psychedelics such as LSA, ayahuasca and mescaline will induce internal hallucinations near consistently at level 5 geometry and above, 1cP-LSD will for most simply go straight into Level 8A visual geometry. This lack of consistently induced hallucinatory breakthroughs means that for most, LSD is limited in depth. When they do occur, they can be described in terms of their variations as lucid in believability, interactive in style, new experiences in content, autonomous in controllability and geometry-based in appearance.
- External hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots)
- Analysis enhancement - This effect is consistent in its manifestation and introspection dominant.
- Anxiety & Paranoia - This effect is not as common at low to moderate doses and is less likely to occur when the basic rules of set and setting are taken into account. It should be noted that this inconsistently induced effect is seemingly more likely to manifest when used with cannabis. This combination should be used with extreme caution if one is not experienced with psychedelics, meaning that the user should adequately pace themselves with a fraction of their usual amount. It is commonly reported that psychedelics can to a certain extent counteract some of the perceived mental cloudiness or intoxicating effects of THC causing the user to in turn use more cannabis than is needed which can often lead to an overwhelmingly anxious headspace or a "bad trip".
- Conceptual thinking
- Creativity enhancement
- Emotion enhancement
- Novelty enhancement
- Personal bias suppression
- Personal meaning enhancement
- Focus enhancement - This effect is experienced exclusively on low or threshold dosages and feels less forced than it does with stimulants.
- Immersion enhancement
- Suggestibility enhancement
- Cognitive euphoria - This component is, generally speaking less consistent and pronounced than it is with substances like psilocybin and MDMA. The mental euphoria experienced on LSD is usually simply due to an enhancement of the user’s current psychological and emotional state coupled with its more regularly occurring effect, physical euphoria.
- Déjà vu
- Increased libido
- Increased music appreciation
- Increased sense of humor
- Memory suppression
- Thought acceleration
- Thought disorganization
- Thought loops
- Time distortion
- Synaesthesia - In its fullest manifestation, this is a very rare and non-reproducible effect. Increasing the dosage can increase the likelihood of this occurring, but seems to only be a prominent part of the experience among those who are already predisposed to synaesthetic states.
- Alcohol - Alcohol's central depressant effects can be used to reduce some of the anxiety and tension produced by 1cP-LSD. However, alcohol can cause dehydration, nausea and physical fatigue which can negatively impact the direction of the trip. Users are advised to pace themselves and drink a portion of their usual amount.
- Benzodiazepines - Benzodiazepines are highly effective at reducing the intensity of 1cP-LSD's effects through the general suppression of brain activity.
- Cannabis - Cannabis strongly intensifies the sensory and cognitive effects of 1cP-LSD. Extreme caution is advised when using this combination as it can significantly increase the chances of a negative psychological reaction like anxiety, confusion and psychosis. Users are advised to start off with only a fraction of their usual cannabis dose and take long breaks between hits to avoid over intake.
- Dissociatives - 1cP-LSD enhances the cognitive, visual and general hallucinatory effects of dissociatives. Dissociative-induced holes, spaces, and voids and internal hallucinations become more vivid and intense on 1cP-LSD. These effects correspond with an increased risk of confusion, delusions, and psychosis.
- MDMA - 1cP-LSD and MDMA are highly synergistic and mutually enhance each other's physical, cognitive, and visual effects. The synergy between these substances is unpredictable, and it is advised to start with markedly lower doses than one would take for each individually. There is some evidence that suggests LSD increases the neurotoxicity of MDMA, which may be relevant to 1cP-LSD as well.
There are currently 0 experience reports which describe the effects of this substance in our experience index.
Additional experience reports can be found here:
Toxicity and harm potential
This toxicity and harm potential section is a stub.
As a result, it may contain incomplete or even dangerously wrong information. You can help by expanding upon or correcting it.
The toxicity and long-term health effects of recreational 1cP-LSD use have not been studied. This is because 1cP-LSD is a research chemical with almost no history of human use.
However, as with LSD and psychedelics in general, it is likely that 1cP-LSD can act as a trigger for those with underlying mental disorders. Those with a personal or family history of mental illness are generally advised not to use this substance, particularly when outside of a supervised medical setting.
It is strongly recommended that one uses harm reduction practices when using this substance.
1cP-LSD has no known toxic dose. However, higher doses increase the risk of adverse psychological reactions. These reactions include anxiety, delusions and panic attacks. Medical attention is usually not needed except in the case of severe psychotic episodes or the ingestion of fake acid (such as 25i-NBOMe or DOB). Administration of benzodiazepines or antipsychotics can help to relieve the acute negative cognitive effects of 1cP-LSD.
Tolerance and addiction potential
This dangerous interactions section is a stub.
As such, it may contain incomplete or invalid information. You can help by expanding upon or correcting it.
Although many psychoactive substances are reasonably safe to use on their own, they can suddenly become dangerous or even life-threatening when combined with other substances. The following list includes some known dangerous combinations (although it is not guaranteed to include all of them). Independent research (e.g. Google, DuckDuckGo) should always be conducted to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit. The following substances are listed on the assumption that 1cP-LSD possesses a similar if not the same dangerous interactions profile as LSD, and may include more due to its status as an unstudied research chemical.
- Lithium - Lithium is commonly prescribed for the treatment of bipolar disorder. There is a large body of anecdotal evidence that suggests taking it with psychedelics significantly increases the risk of psychosis and seizures. As a result, this combination is strictly discouraged.
- Cannabis - Cannabis may have an unexpectedly strong and unpredictable synergy with the effects of LockPicker/Drafts/1cP-LSD. Caution is advised with this combination as it can significantly increase the risk of adverse psychological reactions like anxiety, paranoia, panic attacks, and psychosis. Users are advised to start off with only a fraction of their normal cannabis dose and take long breaks between hits to avoid unintentional overdose.
- Stimulants - Stimulants like amphetamine, cocaine or methylphenidate affect many parts of the brain and alter dopaminergic function. This combination can increase the risk of anxiety, paranoia, panic attacks, and thought loops. This interaction may also result in an elevated risk of mania and psychosis.
- Tramadol - Tramadol is well-documented to lower the seizure threshold and psychedelics may act to trigger seizures in susceptible individuals.
This legality section is a stub.
As such, it may contain incomplete or wrong information. You can help by expanding it.
- Germany: 1cP-LSD is not a controlled substance under the BtMG (Narcotics Act) or the NpSG (New Psychoactive Substances Act). It is legal, as long as it is not sold for human consumption, according to §2 AMG.
- Sweden: Sweden's public health agency suggested classifying 1cP-LSD as a dangerous substance on December 18, 2019.
- United Kingdom: 1cP-LSD is illegal to produce, supply, or import under the Psychoactive Substance Act, which came into effect on May 26, 2016.
- Brandt, Simon D.; Kavanagh, Pierce V.; Westphal, Folker; Stratford, Alexander; Odland, Anna U.; Klein, Adam K.; Dowling, Geraldine; Dempster, Nicola M.; Wallach, Jason; Passie, Torsten; Halberstadt, Adam L. (March 16, 2020). "Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1‐cyclopropanoyl‐d‐lysergic acid diethylamide (1CP‐LSD)". Drug Testing and Analysis. 12 (6): 812–826. doi:10.1002/dta.2789. eISSN 1942-7611. ISSN 1942-7603. OCLC 231680670. PMID 32180350.
- "1cP-LSD". Google Trends. Retrieved July 14, 2020.
- Armstrong, B. D., Paik, E., Chhith, S., Lelievre, V., Waschek, J. A., & Howard, S. G. (2004). Potentiation of (DL)‐3, 4‐methylenedioxymethamphetamine (MDMA)‐induced toxicity by the serotonin 2A receptor partial agonist d‐lysergic acid diethylamide (LSD), and the protection of same by the serotonin 2A/2C receptor antagonist MDL 11,939. Neuroscience Research Communications, 35(2), 83-95. https://doi.org/10.1002/nrc.20023
- Potentiation of MDMA-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists | https://indiana.pure.elsevier.com/en/publications/potentiation-of-34-methylenedioxymethamphetamine-induced-dopamine
- Ecstasy induces apoptosis via 5-HT(2A)-receptor stimulation in cortical neurons. | https://www.ncbi.nlm.nih.gov/pubmed/17572501
- Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN 1556-9039.
- "Betäubungsmittelgesetz (BtMG)" [Narcotics Act (BtMG)] (PDF) (in German). Bundesamt für Justiz [Federal Office of Justice]. July 28, 1981. Retrieved July 14, 2020.
- "Neue-psychoaktive-Stoffe-Gesetz (NpSG)" [New Psychoactive Substances Act (NpSG)] (PDF) (in German). Bundesamt für Justiz [Federal Office of Justice]. November 21, 2016. Retrieved July 14, 2020.
- "§2 Arzneimittelgesetz (AMG)" [§2 Pharmaceutical Act (AMG)] (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved July 14, 2020.
- "Tjugotre ämnen föreslås klassas som narkotika eller hälsofarlig vara" [Twenty-three substances are proposed to be classified as drugs or dangerous goods] (in Swedish). Folkhälsomyndigheten [Public Health Agency of Sweden]. December 18, 2019. Retrieved July 14, 2020.
- "Psychoactive Substances Act 2016". legislation.gov.uk. Retrieved July 14, 2020.